2023 World Conference on Lung Cancer (Posters)-EP03.03. T-Cell Receptor Repertoire Profiling as a Predictive Biomarker for Immunotherapy in Unresectable Stage III Non-small Cell Lung (NSCLC)

EP03.03. T-Cell Receptor Repertoire Profiling as a Predictive Biomarker for Immunotherapy in Unresectable Stage III Non-small Cell Lung (NSCLC) - PDF(Abstract)

Back to course

Pdf Summary

This document presents findings from a pilot study that investigated the role of T-cell receptor (TCR) repertoire profiling as a potential predictive biomarker for immunotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC). The study focused on the use of durvalumab, an immune checkpoint inhibitor, as immunotherapy for locally advanced NSCLC. The researchers performed TCR sequencing on 12 patients receiving durvalumab treatment after concurrent chemoradiation (CCRT) and classified them as responders (complete response or stable disease) or non-responders (progressive disease). They analyzed TCR diversity and the clonal to total TCR sequence ratio using the Oncomine TCR Beta-SR DNA Assay.<br /><br />The results showed that the responders had higher TCR diversity compared to non-responders during durvalumab treatment after CCRT. The Evenness score, which measures TCR diversity, significantly differed between the two groups. Additionally, the responders showed a trend of increased clonal to total TCR sequence ratio after completing durvalumab treatment, while non-responders did not show significant TCR convergence.<br /><br />The researchers concluded that TCR repertoire profiling could be a potential biomarker for predicting response to durvalumab in NSCLC patients. They suggested that measuring TCR diversity and tracking TCR convergence ratio may provide additional useful parameters for predicting immunotherapy treatment response. This study contributes to understanding the immunological profile and prognostic factors of durvalumab treatment in locally advanced NSCLC.<br /><br />Keywords for this study include immunotherapy, T-cell receptor repertoire profiling, and non-small cell lung cancer. The findings were presented in the Tumor Biology - Translational Biology session of the WCLC 2023 conference.

Asset Subtitle

Narumol Trachu

Meta Tag

Speaker Narumol Trachu

Topic Tumor Biology: Translational Biology - IO

Keywords

T-cell receptor repertoire profiling

immunotherapy

predictive biomarker

unresectable stage III non-small cell lung cancer

durvalumab

immune checkpoint inhibitor

locally advanced NSCLC

TCR sequencing

CCRT

Oncomine TCR Beta-SR DNA Assay